EP08.01-064 Serum NY-ESO-1 and XAGE1 Antibodies Predict and Monitor Clinical Responses to Immune Checkpoint Therapy for NSCLC

Immune checkpoint (IC) therapy is the mainstay in the treatment of non-small-cell lung cancer (NSCLC). IC therapy prolonged overall survival (OS) as compared with conventional chemotherapy; however, long-term survival benefits from IC therapy were moderate and limited. IC chemo-combinations highly cost and have high discontinuation rates due to adverse events. A long-term OS of IC monotherapy is very similar to those of IC chemo-combinations. Presently, tumor PD-L1 expression levels/tumor proportion score (TPS) are used as predictive biomarkers of response to IC monotherapy, though the clinical validation and performance are modest.